esc semaglutide cuts risk of heart attack, stroke or death by 57% vs tirzepatide Novo Nordisk to Share Semaglutide

GLP-1Drugs and Eating Disorders The physician, who doubles as Chief Development Officer at Ovid Therapeutics, a biopharmaceutical company focusing on neurological conditions, calls for doctors to consider the link between the neuropsychiatric origins of eating disorders and the current understanding of how GLP-1RAs work on the brain

His key contributions include: Discovery and initial characterization of MOTS-c as the first mitochondrial-encoded nuclear transcription regulator Demonstration of MOTS-c as an exercise-induced factor that improves age-dependent physical decline Elucidation of bi-genomic communication mechanisms between mitochondrial and nuclear genomes Investigation of MOTS-c polymorphisms associated with longevity in specific populations Studies on MOTS-c effects across aging, metabolic disease, and neurological applications His laboratory continues to investigate molecular mechanisms underlying MOTS-c function, therapeutic potential in age-related diseases, and translational applications for human health and longevity

Tiroid Tmr Uyars Hayvanlar zerinde yaplan almalar, semaglutidin medller tiroid karsinomu (MTC) dahil olmak zere baz tiroid tmrlerinin riskini artrabileceini gstermitir

Cancer cell